Efficacy Of Pathadya Churna In The Management Of Grahani D3osha

Phase 2

• Conditions: Health Condition 1: R00-R99- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

• Registration Number: CTRI/2023/10/058300
• Lead Sponsor: Dr Kirti Rahul

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Age: 18-60 years

2. Patients having pratyatma lakshana of Grahanidosha especially –

Atisrushtam or Ativibadhham or Atidravam malapravritti (altered bowel habits),

Ama Mala Pravritti (Sticky stool)

I.Durgandhita Mala Pravritti (Fowl Smelling stool)

II.Pichchhila Mala Pravritti (Mucous mixed stool)

Trushna,

Arochaka,

Vairasya,

Praseka,

Tamaka,

Shoona pada kara,

Asthi-parva ruka,

Chardi,

Jwara,

Louha-ama-gandhi tiktamlodgar

Udara Shoola (Abdominal pain)

Udara Gaurava (Heaviness in abdomen)

Atopa (Bloating)

Able and willing to give written informed consent.

Exclusion Criteria

1. Mixed infection with parasites such as round worms, hook worms etc.

2. Ulcerative colitis, Crohn’s disease, gastric ulcerations and other inflammatory bowel conditions.

3.Infectious disorders like Intestinal tuberculosis etc.

4. Patients with evidence of malignancy.

5. Patents with diabetes mellitus (FBS >126 mg/dl, PP >200 mg/dl), poorly controlled hypertension, Thyroid disorders and any other autoimmune disorders.

6. Amoebic dysentery, acute diarrhea.

7.Lactose intolerance patients.

8.Abuse of drug or alcohol.

9.Presence of other somatic or mental disorder requiring medication.

10.Patients on prolonged medication with NSAIDs, analgesics or any other drugs that may have an influence on the outcome of the study.

11.H/o hypersensitivity to any of the trial drugs or their ingredients.

12.Patients who have completed participation in any other clinical trial during the past 6 months which is interfering with the results of Grahani.

13.Patients with bleeding per rectum.

14. All the types of atisara, Antraja krimija patients and any other conditions interfering with the results of Grahani.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
•Reduction in Signs & Symptoms by Correcting Agni & Ama. <br/ ><br> <br/ ><br>Timepoint: 4 weeks

Secondary Outcome Measures

Name	Time	Method
Improve the quality of life & wellbeing <br/ ><br> To evaluate the safety, sustainability & adverse drug reaction of trial drugTimepoint: 5 weeks